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Abstract
Background: Our previous work showed that mice immunized with attenuated activated syngeneic T cells (aTCV) led to
damping Treg function which resulted in enhancing anti-tumor immunity. It is well known that DC plays a very important
role in controlling Th cell differentiation; whether DC involves Treg attenuation in immunized mice remained unknown. In
this study, we provided evidence that increased mature DC (mDC) after immunization with aTCV skewed Th17
differentiation, which resulted in inhibition of Treg differentiation through IL-6 signaling pathway.
Principal Findings: In the present study, we found that the frequency of mDCs increased dramatically in the immunized
mice accompanied by lower Treg cells compared to the controls. Moreover, both DCs and serum derived from the
immunized mice suppressed Treg differentiation in vitro, respectively. mDCs generated from bone marrow precursor cells in
vitro strongly inhibited Treg development and simultaneously drove Th17 differentiation with elevated IL-6 production.
However, PD-L1, a potent Treg inducer did not show effect on Treg down-regulation. Assay with transwell systems showed
that cell-cell contact was necessary for IL-6 production to a threshold to activate Th17 transcriptional factor RORct and to
inhibit Treg counterpart Foxp3.
Conclusions: Our results implicate up-regulated Th17 development might be one of mechanisms of enhancing anti-tumor
immunity induced by immunization with aTCV, which provide a novel insight in numerous mechanisms responsible for anti-
tumor immunity.
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Introduction
Treg cells have essential roles in maintenance of immune
homeostasis and in regulation of effector T cell responses.
Therefore, Treg cells can inhibit autoimmune reactions and
impede anti-tumor immunity [1]. Depletion of Treg cells in vivo
enhances tumor immunity in mouse models of cancer [2].
Impaired Treg function contributes to the enhanced Th1, CTL
responses and thereby anti-tumor immunity [3,4,5,6]. In our
previous work, we found responses of anti-tumor immunity were
enhanced after immunized with attenuated activated syngeneic T
cells (aTCV) in the mouse model [3]. In this model, frequency and
function of Treg cells were down-regulated, possibly resulted from
the presence of anti-CD25 antibody, as the antibody titer was
raised in mice. Serum adoptive transfer assay showed that the
antibody destroyed Treg cells [4,5]. However, there are other
pathways to down-regulating Treg reported recently. Reports
have shown that both Th17 and Treg differentiation depend on
TGF-b signal. In vitro Treg transcription factor Foxp3 was
activated in the presence of TGF-b, followed by Treg develop-
ment, whereas in the presence of both TGF-b and a widely
expressed pro-inflammatory cytokine IL-6, Th17 transcription
factor RORct was activated which results in Th17 differentiation
[7,8]. As aTCV induces immune response of immunized mice,
both IL-6 and TGF-b are existed soluble factors in vivo, we would
like to ask whether and how Th17 differentiation was affected
when Treg cells were down-regulated in aTCV immunization
mice.
DCs play an important role in T cell activation and
differentiation [9]. In general, the stages of DC development
were delineated as 1) immature DC (imDC), showing low antigen
presenting capacity with little expression of co-stimulatory and
MHC II molecules; 2) mature DC (mDC), possessing the strongest
antigen processing and presenting ability with high expression
levels of co-stimulatory and MHC II molecules on the cell surface.
It is well-known that DCs play a pivotal role in Th cells
differentiation. To response to exogenous or endogenous stimu-
lation, T cells differentiation and proliferation are skewed via
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molecules [9]. In our mouse model immunized with aTCV, in
which Treg cells were down-regulation accompanied with
enhancing immune response, whether and how DCs involved in
Treg and Th17 differentiation remained to be illustrated.
In the current study, we found that mDCs increased dramatically
in aTCV immunized mice, accompanied by Treg decrease
compared to those in control mice. DCs isolated from immunized
mice suppressed Treg differentiation in vitro, which suggested that
immunization stimulated DC maturation and thereby damped
Treg differentiation. To analysis the mechanisms of mDC affected
Treg and Th17 differentiation, we generated both imDCs and
mDCs from bone marrow precursor cells and analyzed their effect
on Treg and Th17 differentiation. We found that mDCs showed a
strong inhibition to Treg differentiation whereas simultaneously
promoting Th17 differentiation. Meanwhile, cell-cell contact was
essential for the inhibition of Treg differentiation and skewing Th17
differentiation resulted from increased level of IL-6 production for
activating RORct expression and suppressing Foxp3 expression. In
contrast, PD-L1 expressed on mDCs, a potential inducer of Treg,
did not show effect on Treg differentiation in our model. Taken
together, we provided evidence that DC maturation was necessary
to promote Th17 differentiation after immunization with aTCV.
Th17 generation was induced though IL-6 signaling pathway. Our
results provide a novel insight in numerous mechanisms responsible
for anti-tumor immunity through stimulation of Th17 differentia-
tion in vivo.
Results
Peripheral Treg down-regulation induced by
immunization with aTCV
As shown in our previous work, immunization with attenuated
activated syngeneic T cells evoked anti-tumor immunity [3]. In this
model, we found thatthe down-regulated Treg cells were involved in
the anti-tumor immunity induced by immunization with aTCV
[4,5].Toassayadditionalmechanismsinvolvedintheanti-immunity
response, we examined immunization kinetics for Treg reduction
first. Compared to the control mice, results obtained from
immunized mice showed that Treg population was reduced
significantly in mice received more than three times immunization
(called effective immunization), whereas Treg numbers did not show
differences in the mice accepted less two times immunization
(Figure 1A). We also found that Treg was not changed in the mice
immunized with attenuated activated B cells, attenuated resting T
cells and attenuated activated allogenic T cells (data not shown). To
addresswhether Tregcells inthymus orinthe periphery were down-
regulated in those received effective immunization, we examined
Foxp3 gene expression in thymocytes, splenocytes and periphery
blood cells (PBMC) by real-time PCR and found that the expression
of Foxp3 was down-regulated in splenocytes and PBMC but not in
thymocytes (Figure 1B). Consistently, CD4
+CD25
+Foxp3
+ Treg
population was decreased in mononuclear cell population from both
PBMC and splenic cells (Figure 1C). These data indicated that inthe
immunized mice, Treg cells existed in periphery (consisted of
induced Tregs and naturally occurring Tregs) were down-regulated
but naturally occurring Treg cells in thymus did not altered. These
results implied that the differentiation of Treg cells in the periphery
might be reduced.
Mature DCs induced by aTCV immunization inhibited
Treg differentiation
As we know DCs play a crucial role in T cell activation and
differentiation. To understand whether DC was responsible for
down-regulation of peripheral Treg cells in this aTCV immuni-
zation model, the changes of DCs were studied by staining with
anti-CD11c–FITC. The mean fluorescent intensity of the CD11c
hi
population was analyzed in both immunized and control mice.
The percentage of CD11c
hi cells was higher in immunized mice
than that in control mice (Figure 2A). To explore whether these
altered DCs were involved in Treg aberrancy after immunization,
CD4
+ T cells from naı ¨ve mice were cultured with purified DCs
from immunized mice or of control mice. The results showed that
DCs from immunized mice obviously inhibited Treg differentia-
tion compared to those from control mice (Figure 2B). Moreover,
to investigate whether aTCV immunization induced DC matura-
tion, we analyzed DCs purified from splenocytes by flow
cytometry. The results showed that the percentage of
CD11c
hiCD86
+ and CD11c
hiMHCII
+ cells were increased in
immunized mice compared to those in control mice (Figure 2C).
These data indicated that immunization with aTCV induced DC
maturation, which, as a consequence, might be involved in Treg
down-regulation.
To investigate the mechanisms of mDCs on Treg differentia-
tion, DCs from bone marrow precursors in naı ¨ve mice were
isolated, and then stimulated with LPS to obtain mature DCs. As
reported, the expression of MHC-II and CD86 was up-regulated
on CD11c
+ cells after LPS stimulation (Figure 2D). To determine
whether these mDCs could inhibit Terg differentiation, mDCs or
imDCs were generated and co-cultured with CD4
+ T cells,respec-
tively. Results showed that only mDCs could inhibit Treg
differentiation dramatically compared with those co-cultured with
imDCs (Figure 2E). Furthermore, to evaluate the inhibitory effect
of mDCs on Treg differentiation in vivo, mDCs and imDCs
generated in vitro were adoptively transferred i.v. to syngeneic mice
3 times at 3-day interval and then Treg was analyzed after three
days on the final infusion. The results showed that the
CD4
+CD25
+Foxp3
+ Treg population was lower in the mice
received mDCs adoptive transfered (Figure 2F). These results
indicated that mature DC was able to inhibit Treg differentiation
in vivo.
mDCs generated from bone marrow evoked Th17
differentiation
Because mDCs are well-known for guidance on Th differenti-
ation by activation Th cells through antigen presenting, we
examined T cell subsets of T cells co-cultured with mDCs. The
results showed that transcription factor T-bet and Gata3 were not
altered, their counterpart cytokines, IFN-c and IL-4 were not
changed. These indicated that Th1 and Th2 subsets were not
affected. In contrast, the expression of RORct was significantly
increased while the expression of Foxp3 decreased simultaneously.
Consistently, the level of IL-17 was significantly increased when
CD4
+ T cells co-cultured with mDCs (Figure 3A). CCR6 gene
expression was also up-regulated in T cells of co-culture system
(Figure S1). These data demonstrated that Th17 population
increased. In line with this, both gene and protein expression of
IL-21 and IL-22 were increased significantly (Figure 3B). The
similar results were found in CD4
+ T cells co-cultured with DCs
from splenocytes of mice immunized with aTCV (Figure S2).
These data indicated that mDCs inhibited Treg differentiation but
promoted Th17 generation.
mDCs inhibited Treg differentiation independent of PD-
L1/PD-1 pathway
PD-L1 (also called B7H1) is a potential inhibitor that acts as a
negative regulated co-stimulatory molecule expressed on mDCs
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could induce a profound increase of CD4
+Foxp3
+ Treg cells
differentiated from naı ¨ve CD4
+ T cells [11]. To point out whether
PD-L1 molecule involved in reduction of Treg after aTCV
immunization, we investigated the inhibitory effect of mDCs on
Treg differentiation using a transwell system. mDCs and CD4
+ T
cells were co-cultured but separately in a transwell system for
blocking cell-cell contact. As shown in Figure 4A, the inhibited
effect on Treg generation was restored without mDC contacting
with CD4
+ T cell. This indicated that cell-cell contact was essential
for mDCs to execute inhibitory effect on Treg differentiation. To
address whether PD-L1/PD-1 involved in the inhibitory effect, we
examined and found that PD-L1 expression was high on mDCs no
matter generated in vitro or obtained from aTCV immunized mice
(Figure 4B–C). Moreover, mDCs were transfected with PD-L1
siRNA. The data showed that PD-L1 expression was 3 times lower
in mDCs after siRNA transfection compared to control as shown
in Figure S3. Further, mDCs generated in vitro or DCs isolated
from mice immunized with aTCV were knocked down with PD-
L1 siRNA, respectively, and then co-cultured with CD4
+ T cells.
The results showed there was no difference in Treg population
when CD4
+ T cells were co-cultured with PD-L1 knockdown
mDCs or normal mDC (Figure 4D, Figure S4 ). This result
provided evidence that PD-1/PD-L1 interaction did not affect
inhibition of Treg differentiation mediated by mDCs (Figure 4D).
Furthermore, when CD4
+ T cells co-cultured with mDCs in the
presence of neutralizing antibody of PD-L1, the Foxp3 expression
was not affected also (Figure 4E). These data suggested that Treg
differentiation inhibited by mDCs is independent of PD-L1/PD-1
pathway.
Figure 1. Peripheral Treg cells reduced in mice after immunization with aTCV. Naı ¨ve mice were immunized with aTCV. Mononuclear cells
were isolated 5 days after immunization. A) The absolute numbers of Treg cells in peripheral blood were assessed in time course experiment. Naı ¨ve
mice were immunized with aTCV at different times. Peripheral blood samples were stained with anti-CD4, anti-CD25 and anti-Foxp3 Ab. B–C,
Mononuclear cells were isolated from thymus, spleen and periphery blood of mice immunized with aTCV for three times, respectively. B) The gene
expression of Foxp3 was assessed by real-time PCR. C) Mononuclear cells from thymus, spleen and peripheral blood were stained with anti-CD4, anti-
CD25 and anti-Foxp3 Abs and the number of Treg cells was calculated, respectively. Data are shown as mean 6 SEM, n=8–12/group, *, p,0.05,
**, p,0.01.
doi:10.1371/journal.pone.0027289.g001
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27289Cell-cell contact played a key role in the effect of mDCs
on differentiation of Treg and Th17
It is well known that IL-6 plays a critical role in promoting Th17
differentiation. To verify whether cell-cell contact evoked IL-6
production, we investigated IL-6 production. The results showed
that the expression of IL-6 gene and protein was much higher in
mDCs co-cultured with CD4
+ T cells compared with those
cultured separately (Figure 5A), meanwhile, RORct expression
increased compared with Foxp3 decreased. Moreover, when
mDCs co-cultured with CD4
+ T cells in the presence of anti IL-6
neutralizing Ab, the expression of Foxp3 was increased while
RORct decreased (Figure S5). These results indicated that mDCs
promoted Th17 differentiation, and this effect might go through
the IL-6 signaling pathway as STAT3 was phosphorylated
significantly (Figure 5B). To investigate how mDCs interacted
with T cells, expression levels of chemokines and chemokine
receptors on CD4
+ T cells and mDCs were examined. Results
showed that CD4
+ T cells mainly expressed CXCR4 and
CXCR6, whereas mDCs expressed CCL7, CCL9, CCL25,
CXCL12 and CXCL16 (Figure 5C). These data indicated that
mDCs secreted chemokines (for example, CXCL12 and CXCL16)
to recruit CD4
+ T cells expressed CXCR4 and CXCR6, which
led to mDC and CD4
+ T cells contacting and evoked IL-6
production.
In order to understand whether the level of IL-6 increased
contributed to Th17 differentiation, the expression levels of genes
related to differentiation of Th1, Th2, Treg and Th17 cells were
assessed by real-time PCR. The data showed that when mDCs
were separated with CD4
+ T cells by a transwell system,
expression of Foxp3 was increased, the expression of RORct
was decreased, consistently with IL-17 production decreased
(Figure 5D). Moreover, the gene expression levels and protein
levels of IL-21 and IL-22 were decreased simultaneously
(Figure 5E). Taken together, these results suggested that cell-cell
contact is necessary for mDCs effect on Treg and Th17
differentiation.
Th17 differentiation evoked by mDCs inducing increased
secretion of IL-6
To evaluate whether the level of IL-6 was changed in the mice
immunized with aTCV, cytokine profiles in serum were assessed.
As shown in Figure 6A, the levels of IL-6 and IL-17 were increased
Figure 2. mDCs inhibited Treg differentiation. Splenocytes were isolated from mice immunized with aTCV for three times. A) Splenocytes were
cultured in plates for 2 hours. The adhered cells were harvested and stained with anti-CD11c Ab. Expression of CD11c was assessed by FACS. B) DCs
were purified from splenocytes using Dynabeads Mouse DC Enrichment Kit and cultured with purified CD4
+ T cells from naı ¨ve mice. After 2-day
culture, cells were stained with anti-CD4, anti-CD25, anti-Foxp3 Abs and analyzed by FACS on gated CD4
+ T cells. C) Purified DCs were stained with
anti-CD11c, anti-CD86 and anti-MHC class II Abs and analyzed by FACS on gated CD11c
hi cells. D–F, Bone marrow precursor cells freshly isolated from
naı ¨ve mice were cultured in vitro in the presence of GM-CSF and IL-4. After 7 days of culture, cells were stimulated with or without LPS for 2 days. D)
These cells were harvested and stained with anti-CD11c, anti-CD86 and anti-MHCII Abs. E) mDCs or imDCs generated in vitro were cultured with
purified CD4
+ T cells from naı ¨ve mice in the presence of TGF-b. After 2 days of culture, cells were stained with anti-CD4, anti-CD25, anti-Foxp3 Abs
and analyzed by FACS on gated CD4
+ T cells. F) mDCs or imDCs generated in vitro were adoptively transferred into naı ¨ve mice. After 3 days, PBMC
were isolated and stained with anti-CD4, anti-CD25, anti-Foxp3 Abs. Percentage of CD4
+CD25
+Foxp3
+ cells was analyzed by FACS on gated CD4
+ T
cells. Data are shown as mean 6 SEM, n=8–12/group, *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0027289.g002
Figure 3. Differentiation of Th17 co-cultured with mDCs. A) Purified CD4
+ T cells from naı ¨ve mice were cultured with mDCs generated in vitro
in the presence of TGF-b. After culture, gene expression of T-bet, Gata3, Foxp3 and RORct were analyzed by real-time PCR. IFN-c, IL-4, IL-10 and IL-17
production were assessed by FlowCytomix kits. B) Gene expression and cytokine profile relative to Th17 cells were assessed. Data are representatives
of three independent experiments. *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0027289.g003
Activated Syngeneic T Cell Enhance Th17 Generation
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27289in sera isolated from the mice immunized with aTCV compared
with the control mice. Compatibly, percentage of Th17 in CD4
+ T
cell population was increased significantly (Figure 6B). The gene
expression of IL-6, RORct and IL-22 were also increased
(Figure 6C). To verify the sera from immunized mice inhibited
Treg differentiation, CD4
+ T cells cultured with immunized
mouse serum in the presence of TGF-b. The data showed that sera
from immunized mice conveyed significant inhibition roles on
Treg differentiation and increase Th17 differentiation (Figure 6D).
These results suggested that increased mDCs, which promoted IL-
6 secretion, induced Th17 differentiation and inhibited Treg
generation in vivo.
Figure 4. Inhibition of Treg differentiation was independent of PD-1/PD-L1 pathway. A) Purified CD4
+ T cells were cultured with mDCs
together or separately by transwell systems. Cells were harvested and stained with anti-CD4, anti-CD25 and anti-Foxp3 Abs. Foxp3 expression was
assessed by FACS on gated CD4
+CD25
+ T cells. B-C, The frequency of CD11c
+PDL-1
+ cells was analyzed by FACS. B) DCs were purified from
splenocytes of immunized mice using Dynabeads Mouse DC Enrichment Kit and stained with anti-CD11c and anti-PDL1 Abs. C) DCs generated from
bone marrow precursor cells in vitro stimulated with or without LPS were stained with anti-CD11c and anti-PDL1 Ab. D) Purified CD4
+ T cells from
naı ¨ve mice were cultured with PD-L1 knockdown mDCs in the presence of TGF-b. After 2 days of culture, cells were stained with anti-CD4, anti-CD25
and anti-Foxp3 Abs and analyzed by FACS on gated CD4
+ T cells. E) Purified CD4
+ T cells from naı ¨ve mice were cultured with mDCs in the presence of
TGF-b and anti-PD-L1 neutralizing antibody for 2 days, cells then were stained with anti-CD4, anti-CD25 and anti-Foxp3 Abs and analyzed on gated
CD4
+ T cells by FACS. Data are representatives of three independent experiments. *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0027289.g004
Activated Syngeneic T Cell Enhance Th17 Generation
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27289Discussion
Treg cells represent a substantial obstacle for development of
cancer immunotherapy. Numerous strategies were under active
investigation to achieve Treg depletion in vivo, including low dose
cyclophosphamide, interleukin-2 immunotoxins or CD25 antibody
treatment [12,13,14,15]. There were very few studies through
syngeneic cell immunization to reduce Treg cells until we reported
our studies in 2006 [3].
In our previous studies, we found that immunization with
aTCV enhanced Th1 and CTL activity, leading to augmentation
of anti-tumor immunity accompanied by damped Treg function
[5]. In this study, we confirmed that Treg population significantly
reduced only in the mice immunized with aTCV, with no
Figure 5. The roles of mDCs on differentiation of Treg cells and Th17 were dependent on cell-cell contact. Purified CD4
+ T cells were
cultured with mDCs together or separately by transwell systems. A) IL-6 gene expression and production of IL-6 cytokine were analyzed. B)
Phosphorylation of STAT3 in total cells which included T cells and DCs was detected by Western blotting. C) Chemokine gene expression in DCs and
chemokine receptor expression in T cells were analyzed by real-time PCR. D) Gene expression and cytokine production of Th1, Th2, Treg cells and
Th17 were analyzed. E) Gene expression and cytokine profile relative to Th17 cells were assessed. Data are representative of three independent
experiments. ***, p,0.001.
doi:10.1371/journal.pone.0027289.g005
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attenuated activated B cells, attenuated resting T cells and
attenuated activated allogenic T cells (data not shown). As
syngeneic T cells are different from allogenic T cells regarding
to their MHC molecules, syngeneic aTCV could down-regulate
Treg cells, whereas allogenic aTCV could not, suggesting that
MHC molecules were not involved in the Treg reduction in this
model. In the present study, we found that immunization with
aTCV did not affect nTreg development in thymus. However,
Treg cells in periphery were decreased, indicating that Treg
reduction might be to some extent due to the generation of
decreased Treg cells in periphery.
DCs play a very important role in altering T cell differentiation
upon cell-cell contact. By immunization, DCs underwent a
maturation process resulted in morphological and functional
changes by which DCs were divided into two conventional subsets:
imDCs and mDCs [16,17]. Among them, which population is
responsible for Treg down-regulation is unclear. In this study, we
showed that mDCs, which increased in spleen of aTCV
immunized mice, could significantly inhibit Treg differentiation
but promote Th17 development, as well as those of cultured from
bone marrow precursors in vitro, suggesting that DC maturation
had impact on Treg and Th17 differentiation. Our data were
consistent with that described previously [18,19,20], these authors
found that Treg cells could effectively suppress CD4
+CD25
2 T
cell activation in a co-culturing system where freshly isolated
splenic DCs were used as APCs, while stimulation of DCs with
LPS reversed Treg-mediated suppression and restored T cell
proliferation. In these reports, IL-6 secreted by DCs was required
for overcoming suppression. Our data supported that maturation
of DCs affected Treg differentiation also. While the mechanisms of
DC maturation in aTCV immunized mice remains unknown and
more extended study to identify how the DC maturation induced
by aTCV immunization in vivo is under investigation.
DCs stimulated with LPS could induce IL-6 production [21].
IL-6 promotes the generation of Th17 cells from naı ¨ve T cells
together with TGF-b. As immunization with aTCV initiated DC
maturation, IL-6 increased in vivo which was consistent with the
up-regulation of RORct, IL-17 and IL-22. We also found that
CXCL12 and CXCL16 on mDCs were highly expressed. These
results implied that mDCs through up-regulation of chemokines
recruited CXCR4 and CXCR6 of CD4
+ T cells [22,23,24] and
then, differentiated T cells to Th17. In our study, Th2 subset did
not alter obviously. It is consistent with the report that TGF-b is
found to interfere with Th2 differentiation in vitro [25]. Although
we found that Th1 increased after immunization with aTCV [4],
Figure 6. aTCV promoted differentiation of Th17 in vivo. Naı ¨ve mice were immunized with aTCV for three times. Five days after final
immunization, sera and splenocytes were isolated. A) The levels of cytokine production were measured by FlowCytomix kits as indicated. B)
Splenocytes were restimulated with PMA/ionomycin for 5 h and intracellular IL-17 production was measured by flow cytometry. C) Gene expression
was assessed as indicated by real-time PCR. D) Purified CD4
+ T cells from naı ¨ve mice were cultured with 2% serum from aTCV immunized or control
mice with or without TGF-b. After 2-day culture, cells were stained with anti-CD4, anti-CD25, anti-Foxp3 Abs and analyzed by FACS on gated CD4
+ T
cells. Data are representatives of three independent experiments. *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0027289.g006
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T-bet and IFN-c. The reason might be that existed TGF-b,a
critical antagonist for Th1 differentiation, affects expression of
IFN-c and T-bet [26,27]. Our study supported and was consistent
with previous reports which demonstrated that TGF-b blocked
Th1 and Th2 differentiation but promoted Th17 differentiation
simultaneously [28]. This is very important to add knowledge
about mDC involved in Th differentiation in immune response.
IL-10 is a cytokine with anti-inflammatory properties and secreted
by several immune cells [29]. In our experiment system, we did
not detected high levels of IL-10 production.
PD-L1, also called B7H1, as a co-stimulatory molecule
expressed on mDCs is a potential inhibitor in immune response
[10]. It was reported that blockade of an interaction between PD-
L1 and PD-1 would result in aberration on expansion and function
of Treg cells [11]. However, some studies showed that stimulation
of PD-L1 molecule could induce a profound increase of
CD4
+Foxp3
+ Treg cells differentiated from naı ¨ve CD4
+ T cells
[30]. As we found that mDCs involved in impaired Treg
differentiation, we hypothesized that silencing PD-L1 would
restore Treg differentiation. Unexpectedly, the results showed
neither silencing PD-L1 expression by RNAi, nor blocking PD-L1
with neutralizing antibody, could restore inhibition of Treg
differentiation induced by mDCs. These data suggested that PD-
1/PD-L1 pathway is not involved in the process. However, this
result implied strongly that some soluble factors derived from
mDCs are accountable for Treg reduction. By using the transwell
system, we confirmed that mDC released IL-6 to prompt Th17
differentiation and inhibit Treg differentiation simultaneously.
These were supported by elevated IL-6, IL-17, IL-21 and IL-22
production in vivo and in vitro. In another word, mDCs are very
important to skew CD4
+ T cells into Th17 but inhibit Treg
differentiation. We identified that only mDC could promote Th17
differentiation in receipt mice by adoptive transfer assay.
However, in the current study, we failed to detect increased IL-
23 production both in vitro and in vivo. As a member of the IL-12
family, IL-23 is not involved in the initial differentiation but might
serve to expand and stabilize Th17 responses [31]. How Th17 is
expanded and stabilized in the aTCV immunized mouse model
are now being investigated.
Why separation of mDCs and CD4
+ T cells with the transwell
system blocked Th17 differentiation and meanwhile rescued Treg
differentiation? By analysis chemokine profile, we found that,
although expression levels of CXCL12 and CXCL16 on mDCs
were not changed (data not shown), the transwell membrane
blocked cell-cell contact of mDC and CD4
+ T cell which was
necessary for IL-6 production. From these data, we concluded that
mDCs contacted with CD4
+ T cells resulted in IL-6 production
increased. Without IL-6, not Th17 but Treg cells were
differentiated in the presence of TGF-b. This suggested that cell-
cell contact is necessary for polarizing cytokine IL-6 production.
This is very important to propose that aTCV immunization could
evoke a seesawing effect in vivo: up-regulation of Th17 differen-
tiation and down-regulation of Treg differentiation, which led to
enhancing immune response and further arresting tumor growth in
vivo [3–5].
In recent years, the function of Th17 cells and IL-17 is unclear
in anti-tumor immunity [32]. Several reports observed that Th17
cells and IL-17 had been found in various human tumors
[33,34,35,36]. In contrast, the expression of IL-17 in a
hematopoietic origin tumor was reported to promote protection
in immunocompetent hosts including to rise tumor-specific CD8
+
T cell [37,38,39,40]. Therefore, immunotherapy targeting on
enhancing Th17 activity might benefit cancer patients. Our study
offers a model to understand how to enhance Th17 function via
simultaneously inhibiting Treg in vivo.
Taken together, our results implicated that DC maturation
played an important role in promoting Th17 differentiation and
inhibiting Treg generation. After aTCV immunization, the
expression of RORct and the protein levels of IL-6, IL-17
increased whereas Foxp3 expression decreased in vivo (Figure 7).
Based on our finding that aTCV could enhance DC maturation,
we suggest that up-regulated Th17 development might be one of
mechanisms of enhancing anti-tumor immunity induced by
immunization with aTCV, which provide a novel insight in
numerous mechanisms responsible for anti-tumor immunity.
Given these considerations, more extended study to identify how
the DC maturation induced by aTCV immunization in vivo is
under investigation.
Figure 7. Schematic model of Th17 differentiation with aTCV immunization. After aTCV immunization, increased mDCs interacted to T cells,
which induced IL-6 production and Th17 differentiation followed by inhibition of Treg generation.
doi:10.1371/journal.pone.0027289.g007
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Ethical treatment of animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Animal Care and User
Committee guidelines. The protocol was approved by the
Committee on the Ethics of Animal Experiments of Shanghai
Jiao Tong University School of Medicine (Permit Number:
2010039).
Animals
6–8 week-old female C57BL/6 mice were purchased from
Shanghai Slac Laboratory Animal Co., and were kept under
pathogen-free conditions at the animal core facility of Shanghai
Jiao Tong University School of Medicine.
Attenuated activated syngeneic T cell preparation and
administration
Attenuated activated syngeneic T cells were prepared and
administrated for immunization as described in our previous
report. Briefly, Splenocytes from naı ¨ve mice were stimulated with
5 mg/ml ConA (Vector Laboratories, Burlingama, CA, USA) in
complete DMEM (DMEM with 10% fetal calf serum, 10 mM
HEPES, 50 mM b-mercaptoethanol, 2 mM L-glutamine and
50 IU/ml penicillin-streptomycin) in 25 ml flasks for 72 h. The
cells were collected and washed three times with PBS (pH 7.4). T
cells were then purified using Dynabeads coated with specific
antibodies by negative selection (Dynal Biotech, Oslo, Norway).
The purity of T cells obtained from culture was greater than 95%.
Purified T cells were irradiated at 3000 rad. Mice were immunized
by intraperitoneal and subcutaneous injection with 5610
6 cells/
mouse. The mice received similar immunizations every 5 days.
Five days after final immunization, the mice were killed.
CD4
+ T cell isolation
Spleens from naı ¨ve mice were freshly removed and prepared for
single-cell suspensions. CD4
+ T cells were negatively isolated from
the resulting splenocytes using magnetic bead separation. Briefly,
splenocytes were depleted for CD8
+, B220
+, CD16
+, Gr-1
+ and
Ly76
+ cells using biotin-labeled specific mAb (BD Biosciences
PharMingen, San Diego, CA, USA), anti-biotin magnetic beads,
and an LD magnetic bead column (Miltenyi Biotec, Auburn, CA,
USA). The purity of CD4
+ T cells was always greater than 95%, as
indicated by flow cytometry.
Dendritic cell from spleen isolation
Fresh spleens were removed and prepared for single-cell
suspensions. DCs were purified ($93%) using Dynabeads Mouse
DC Enrichment Kit (Invitrogen Dynal AS, Oslo, Norway)
according to the manufacturer’s instructions.
Dendritic cell Generation
Bone marrow-derived dendritic cells were prepared using
methods as described by Inaba et al. (1992). Briefly, bone marrow
cells were flushed from the femurs of naı ¨ve C57BL/6 mice using
complete RPMI 1640 (cRPMI) medium (RPMI 1640 medium
(Sigma, Oakville, ON) supplemented with 10% fetal bovine serum
(FBS, Gibco, Burlington, ON), 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM glutamine and 2-mercaptoethanol). Red blood
cells were lysed by adding 1 ml ACK buffer (Lonza, Walkersville,
MD). The bone marrow cells were washed twice with cRPMI and
plated at a density of 2610
6 cells/ml in 6-well plates. Cells were
cultured infresh DC culture medium(cRPMImedia with 10 ng/ml
GM-CSF and 1 ng/ml IL-4 (PeproTech, Rocky Hill, NJ). On days
3 and 5, non-adherent cells were washed away, and fresh DC
culture medium was added to the culture plate at these time points.
On day 7, 100 ng/ml LPS (Sigma) were added to stimulate DCs to
mature. On day 9 BMDCs were purified ($93%) using Dynabeads
Mouse DC Enrichment Kit (Invitrogen Dynal AS, Oslo, Norway)
according to the manufacturer’s instructions.
DC with CD4
+ T cell co-culture
Purified CD4
+ T cells from naı ¨ve mice were resuspended at the
concentration of 1610
6/ml in cRPMI and cultured with fresh
purified DCs from spleens of mice or from cultured DCs in vitro at
the ratio of 5:1 in the presence of 2 mg/ml of platebound anti-CD3
(clone 145-2C11, eBioscience), 2 ug/ml soluble anti-CD28 (clone
37.51, eBioscience), 2 ng/ml TGF-b (R&D Systems) and 100 U/
ml IL-2 (R&D Systems). After 24 hr, the cells were harvested and
gene expression was analyzed by real-time PCR. After 48 hr-
culture, the cells were harvested and stained with anti-CD4, anti-
CD25 and anti-Foxp3 Ab. Foxp3 expression were assessed by
FACS. A transwell system (0.4 mm pore, Costar, Corning Inc.,
Corning, NY, USA) was used in the co-culture. Purified CD4
+ T
cells were seeded in the apical chamber of transwell with 0.4 mm
pore. DCs were cultured in the lower compartment of the
transwell. The cells were maintained in a 37uC 5% CO2
incubator. After 24 hr or 48 hr of culture, gene expression, cell
surface markers and cytokine production were analyzed.
siRNA oligo transfection
PD-L1 small interfering RNA (siRNA) was designed and
synthesized at Shanghai GenePharma (Shanghai, China). mDCs
were precoated on 12-well plates (Costar, Corning Incorporated).
The PD-L1 siRNA oligo and the GenePORTER reagent (Gene
Therapy Systems) were diluted with serum-free medium, then
mixed and incubated at room temperature for 20 min. Culture
medium was aspirated from the cells, the mixture added to the cells
and the culture incubated at 37uC for 3–5 h. Post-transfection, 1
volume of medium containing 20% FCS was added and the culture
incubated overnight under 5–10% CO2 at 37uC. After 24 hr,
addition of purified CD4
+ T cells was added in the presence of
2 ug/ml of anti-CD3(clone 145-2C11, eBioscience), 2 ug/ml
soluble anti-CD28 (clone 37.51, eBioscience), 2 ng/ml TGF-b
(R&D Systems) and 100 U/ml IL-2 (R&D Systems) for 2days. After
this period of culture, cell surface markers were assessed.
Flow Cytometry analysis
Cells were washed with PBS and then stained with various
fluorochromes using standard methods provided by the manufac-
turers. Antibodies used for surface staining of FITC labeled anti-
CD4, -CD11c, PE labeled anti-CD86, -MHCII, -PD-L1 and APC
labeled anti-CD25 Abs were purchased from BD PharMingen.
For detection of Foxp3
+ cells or IL-17
+ cells, these cells were fixed
and permeabilized according to the manufacturer’s instructions
and incubated with PE labeled anti-Foxp3 mAb, PE labeled anti-
IL-17 mAb (e-Bioscience, San Diego, CA, USA), respectively.
Isotype-matched antibodies were used as controls, and cells were
preincubated with mouse IgG to avoid nonspecific binding to
FcRs. All samples were analyzed using a BD FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA, USA).
Cytokine measurement
FlowCytomix kits which measure cytokines IL-6, IL-10, IL-17,
IL-22, IL-23, IFN-c and IL-4 were purchased from Bender
MedSystems (Vienna, Austria). The levels of IL-21 were measured
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according to the manufacturer’s instructions. Standard curves for
each cytokine were generated by using the reference cytokine
concentrations supplied by the manufacturers. Raw data of the FC
bead assay were analyzed by FlowCytomixPro1.0 software.
RNA extraction and gene expression analysis
RNA extraction and real-time PCR was performed as
previously reported [3]. The primers used in this study were
showed in table 1.
Western blot analysis
Cells were harvested and lysed with 50 mM Tris–HCl buffer
(pH 7.4) containing 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor
mixture (Roche Applied Science). For each sample, equal amounts
of 30 mg protein were electrophoresed and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). Membranes
were blocked in 5% nonfat milk and 0.1% Tween 20 in PBS, and
probed with primary antibodies of STAT3, phospho-STAT3 and
b-actin (Cell Signaling Technology) diluted in 1% nonfat milk and
0.1% Tween 20 in PBS. Membranes were washed 3 times with
PBS-Tween (PBST), and probed with donkey anti-goat horserad-
ish peroxidase-conjugated secondary antibodies (Santa Cruz
Biotechnology) in 1% nonfat milk in PBST. Membranes were
washed 3 times for 20 min with PBST. The enhanced chemilu-
minescence (ECL) system (Amersham Pharmacia Biotech, Piscat-
away, NJ) was used to visualize bands.
Adoptive transfer
2610
6 DCs were injected into naı ¨ve mouse by intravenous
injection (i.v.). The CD4
+CD25
+Foxp3
+ T cells in peripheral
blood mononuclear cells (PBMC) of recipient mice were analyzed
by FACS after 3 days.
Statistical analysis
Except where indicated otherwise, data are expressed as the
mean6SEM. Student’s t-test was used to analyze the differences
between groups. Statistically significant changes were first
determined by one-way analysis of variance and then by Student’s
paired or unpaired 2-tailed.
Supporting Information
Figure S1 CCR6 gene expression on T cells. Purified
CD4
+ T cells from naı ¨ve mice were cultured with or without
mDCs generated in vitro in the presence of TGF-b. After culture,
CCR6 gene expression was assessed in purified T cells by real-time
PCR. Data are representatives of three independent experiments.
*, p,0.05.
(TIF)
Figure S2 Differentiation of Th17 co-cultured with DCs
from splenocytes of immunized mice. A) Purified CD4
+ T
cells from naı ¨ve mice were cultured with DCs isolated from
splenocytes of immunized mice in the presence of TGF-b. After
culture, gene expression of T-bet, Gata3, Foxp3 and RORct were
analyzed by real-time PCR. IFN-c, IL-4, IL-10 and IL-17
production were assessed by FlowCytomix kits. B) Gene expression
and cytokine profile relative to Th17 cells were assessed. Data are
representatives of three independent experiments. *, p,0.05,
**, p,0.01.
(TIF)
Figure S3 siRNA suppressed PD-L1 expression. mDCs
generated in vitro were knocked down by siPD-L1. PD-L1 gene
Table 1. Specific primers used in real-time PCR analysis.
Gene Prime: Fw: 59-39 Prime: Rv: 59-39
IL-6 TTCCATCCAGTTGCCTTCTTG GGGAGTGGTATCCTCTGTGAAGTC
IL-21 GCATGCAGCTTTTGCCTGTT CACGAGGTCAATGATGAATGTCTTA
IL-22 CAACACCCGGTGCAAGCT TCCTTGGCCAGCATAAAGGT
IL-23 TGGCTGTGCCTAGGAGTAGCA GCATGCAGAGATTCCGAGAGA
RORct CACGGCCCTGGTTCTCAT GCAGATGTTCCACTCTCCTCTTCT
Foxp3 AGGAGCCGCAAGCTAAAAGC TGCCTTCGTGCCCACTGT
T-bet ATGTTTGTGGATGTGGTCTTGGT CGGTTCCCTGGCATGCT
Gata3 CAAGCTTCATAATACCCCTGACTATG GCGCGTCATGCACCTTTT
CCR1 GCAGAGAGGAAAGACAGAACACTTT TCTTTTTTATGGTTGGCTGCCTAT
CCR9 TAGTTTGGAGCCACCTGTCAGA GAAGTGGATTGGGAGCAAGACT
CXCR4 CTTTGTCATCACACTCCCCTT GCCCACATAGACTGCCTTTTC
CXCR6 CCAAGTCATTTGCTTGCTCATTT TCAATATCTTGAACATGGCCATAGA
CCL7 GGGTCGAGGAGGCTATAGCAT TTCTGTTCAGGCACATTTCTTCA
CCL9 CAACAGAGACAAAAGAAGTCCAGAG CTTGCTGATAAAGATGATGCCC
CCL25 TTACCAGCACAGGATCAAATGG GGTTGCAGCTTCCACTCACTT
CXCL5 TCCCCAGCGGTTCCATCT CGTGAACAGCAACAGAAATGC
CXCL9 TGGAGCAGTGTGGAGTTCGA CCTCGGCTGGTGCTGATG
CXCL12 AGAGCCAACGTCAAGCATCTG TCTTCAGCCGTGCAACAATC
CXCL16 GCAGTGTCGCTGGAAGTTGTT GATCCAAAGTACCCTGCGGTATC
b-actin TGTCCA CCT TCC AGC AGA TGT AGC TCA GTA ACA GT C CGC CTA G
doi:10.1371/journal.pone.0027289.t001
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tives of three independent experiments. ***, p,0.001.
(TIF)
Figure S4 PD-L1 Knockdown DCs from immunized
mice did not restore Treg differentiation. Purified CD4
+
T cells from naı ¨ve mice were cultured with PD-L1 knockdown
DCs from splenocytes of mice immunized with aTCV in the
presence of TGF-b. After 2 days of culture, cells were stained with
anti-CD4, anti-CD25 and anti-Foxp3 Abs and analyzed by FACS
on gated CD4
+ T cells. Data are representatives of three
independent experiments.
(TIF)
Figure S5 Inhibition of Treg differentiation was depen-
dent on IL-6. Purified CD4
+ T cells from naı ¨ve mice were
cultured with mDCs in the presence of TGF-b and anti-IL-6
neutralizing antibody for 2 days, cells then were stained with anti-
CD4, anti-CD25 and anti-Foxp3 Abs and analyzed on gated
CD4
+ T cells by FACS. Data are representatives of three
independent experiments. **, p,0.01.
(TIF)
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